Lantern Pharma Inc. Restricted Cash and Cash Equivalents
Lantern Pharma Inc. (LTRN) had Restricted Cash and Cash Equivalents of $52.52 million as of 2021-12-31, per its 10-K filed 2022-03-10.
Discontinued › Balance Sheet › Assets › Restricted Cash and Cash Equivalent
us-gaap:RestrictedCashAndCashEquivalents · last filed 2022-03-10
- 2021-12-31: Restricted Cash and Cash Equivalents $52.52M.
- 2021-09-30: Restricted Cash and Cash Equivalents $55.67M.
- 2020-12-31: Restricted Cash and Cash Equivalents $19.23M.
- 2020-09-30: Restricted Cash and Cash Equivalents $20.80M.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2021-12-31 | $52.52M 10-K · filed 2022-03-10 |
| 2021-09-30 | $55.67M 10-Q · filed 2021-11-01 |
| 2020-12-31 | $19.23M 10-K · filed 2022-03-10 |
| 2020-09-30 | $20.80M 10-Q · filed 2021-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |